Fibromyalgia
Are you tired of living with fibromyalgia? Explore natural remedies and find relief with Fungitown. We are dedicated to helping you manage your symptoms and improve your quality of life. Discover the power of mushrooms in reducing pain, fatigue, and inflammation. Join the Fungitown community and start growing your own mushrooms at home today!
Looking for a natural solution to manage your fibromyalgia symptoms? Embrace the power of microdosing with Fungitown. Our innovative approach combines the benefits of microdosing with the unique properties of mushrooms. Experience reduced pain, increased energy, and improved overall well-being. Join our community and unlock the potential of microdosing for fibromyalgia relief. Start your journey with Fungitown today!
It is not the intention of Fungitown to provide specific medical advice but rather to provide users with information to better understand their health and their diagnosed disorders. Specific medical advice will not be provided, and FungiTown urges you to consult with a qualified physician for diagnosis and for answers to your personal questions.
Participate in a study: Psilocybin in patients with fibromyalgia: Brain biomarkers of action (PsiloPain)
Chronic pain is one of the leading causes of disability worldwide. Fibromyalgia, a condition characterised by widespread chronic pain, remains poorly understood with limited options for treatment. Psilocybin may provide an opportunity to affect the personal impact of pain in people living with fibromyalgia, and here, we wish to better understand how it may work.
For this study, we recruited adults with fibromyalgia who were deemed eligible at screening will attend eight study visits over eight weeks. Participants received psilocybin at least once, with a dose up to 25mg. Across these eight visits, there were three magnetic resonance imaging (MRI) scans, six electrophoretogram (EEG) recordings, and a range of questionnaires and interviews. There will also be a remote follow-up period of six months following the final study visit.
Please note that Psilocybin is not a licenced drug or treatment for fibromyalgia and therefore cannot be prescribed.
We have completed this study and are no longer accepting applications. We will publish the results of the study in due course and post updates on this website.
For any enquiries please email psychedelicresearch@imperial.ac.uk.
Knowledge, Perceptions, and Use of Psychedelics among Individuals with Fibromyalgia
Fibromyalgia (FM) is a difficult to treat chronic pain condition for which there is strong interest in alternative treatments. There is growing interest in the potential of psychedelic substances (e.g., psilocybin) in conjunction with psychotherapy to treat chronic pain. Via a cross-sectional, anonymous, online survey, we aimed to characterize knowledge, perceptions, and past use of serotonergic (“classic”) and non-serotonergic psychedelics among a population of individuals with FM, and to investigate interest in psychedelic-based FM treatments. Among a North American population of 354 participants with FM, 29.9% reported past use of a psychedelic, with lysergic acid diethylamide (LSD) and psilocybin mushrooms being most commonly used. Perceptions of benefit from psychedelic use were generally neutral (59.4%) or positive (36.8%), with <3% reporting negative impacts on overall health or pain symptoms. Among 12 participants who used psychedelics with intentions of treating chronic pain, 11 reported improved symptoms. Regardless of past use, the majority of participants believed that psychedelics have potential for chronic pain treatments and would be willing to participate in a psychedelic-based clinical trial for their pain. These findings support the need for additional studies to understand the potential and effectiveness of psychedelic substances in managing FM symptoms.
Microdosing psilocybin for chronic pain: a case series
Psychedelic serotonergic agonists such as psilocybin have recently been shown to produce sustained benefit in refractory depression, end of life anxiety, and addiction when administered in hallucinogenic doses and coupled with psychotherapy. Although it has been suggested that similar high-dose protocols may help chronic pain conditions, there are few published clinical trials of psychedelics for pain. The use of these agents in subpsychedelic doses for chronic pain management has received even less attention. This case series details the experiences of 3 individuals who have used low-dose psilocybin to manage chronic neuropathic pain. Although the nature and etiology of each patient’s pain vary, they share a common experience, including inefficacy of current therapeutics and decreased quality of life. Through self-administration of psilocybin, these patients have achieved robust pain relief with decreased reliance on traditional analgesic medications. Despite varying preparations and uncertain potencies, the analgesic effects for all 3 patients occurred at doses without a psychedelic experience and with minimal cognitive or somatic adverse effects. Furthermore, the efficacy of pain relief and, in some cases, the duration of the effect were magnified when coupled with functional exercise. In addition, in 1 case, repeated dosing seemed to produce increased relief, suggesting a possible long-term plasticity-mediated effect. These commonalities highlight psilocybin’s therapeutic potential in the treatment of chronic pain that warrants further investigation.
Copyright © 2022 International Association for the Study of Pain.
